DMT for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

DMT for Health & Longevity

Created on 06/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

DMT is a fast-acting psychedelic, found in plants and made in trace amounts by the body, studied as a rapid treatment for severe depression. A single supervised dose may produce a large, fast drop in depression and suicidal thoughts lasting weeks. Risks appear manageable when carefully screened. The evidence base is thin, early-stage, and unsettled. (Full Review)

Protocol

Model
Single supervised session
In a clinic with psychological preparation beforehand and integration afterward
Route
Inhalation or injection
Not swallowed alone; gut and liver MAO-A destroy it. Intravenous infusion can extend the experience
Dosing
Low starting dose, escalated
For example an inhaled 15 mg dose before a 60 mg dose within the same day, escalated only if tolerated
Time to effect
Depression
Within a day
Antidepressant effects appeared within a day and lasted weeks, far faster than standard antidepressants
Suicidal ideation
Within 1 day
Thoughts of suicide decreased quickly after dosing in small trials
Acute experience
Seconds to minutes
Begins within seconds to minutes of inhalation or injection; the experience lasts about 10–30 minutes

Benefits

Contraindications
  • Personal or family history of psychotic disorders (e.g., schizophrenia) or bipolar disorder
  • Significant cardiovascular disease, uncontrolled hypertension, or recent cardiac events
  • Pregnancy or breastfeeding
    •
Key Interactions
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, ayahuasca β-carbolines)
  • Serotonergic antidepressants, SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine)
  • Other serotonergic over-the-counter products (dextromethorphan, St. John's Wort)
  • Supplements with serotonergic or MAO-inhibiting activity (5-HTP, L-tryptophan, SAMe, syrian rue extracts)
  • Other psychoactive interventions (stimulants, other serotonergic psychedelics)
    •

Risk & Side Effects

  • High: Acute cardiovascular stimulation; intense and potentially frightening psychological experience
    •
  • Medium: Nausea and vomiting; acute psychological reactions requiring support
    •
  • Low: Serious psychiatric events in vulnerable individuals; hallucinogen persisting perception disorder
    •
  • Speculative: Reproductive and developmental toxicity; serotonin toxicity with interacting drugs
    •

Monitoring

Marker Target Why
Blood pressure ~110–120 / 70–80 mmHg at rest Screens cardiovascular risk before, and tracks the acute rise during, a session
Heart rate ~60–80 bpm at rest Detects baseline cardiovascular concerns and the transient rise during dosing
ECG (heart-rhythm tracing) Normal sinus rhythm, no significant abnormality Identifies rhythm or conduction problems that raise the risk of acute cardiovascular stimulation
Depression rating (e.g., MADRS or PHQ-9) As low as achievable; remission thresholds are scale-specific Establishes a mood baseline and measures whether a session produces meaningful improvement

Cadence: Continuous blood pressure and heart-rate monitoring during each session; symptom and safety follow-up at day 1, day 7, and then approximately monthly for up to three months

Qualitative Assessment

  • Mood and emotional state in the days and weeks after a session
  • Quality and meaningfulness of the acute experience, which may relate to outcome
  • Energy levels and engagement with daily activities
  • Sleep quality, as an indirect indicator of mood improvement
  • Any lingering perceptual disturbances or distress requiring follow-up
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.